| Budget Amount *help |
¥35,100,000 (Direct Cost: ¥27,000,000、Indirect Cost: ¥8,100,000)
Fiscal Year 2017: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2015: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2014: ¥15,080,000 (Direct Cost: ¥11,600,000、Indirect Cost: ¥3,480,000)
|
|---|
| Outline of Final Research Achievements |
This study includes (1) “Generation of replication-incompetent virus vaccines against influenza”, and (2) “Anti-tumor therapy using oncolytic adenoviruses in dogs. First, we successfully established MDCK cells stably expressing each HA (H1-H15), which were required to generate replication-incompetent recombinant viruses with each HA. Actually, we generated a couple of such viruses and found their immunogenicity. Second, we established adenovirus reverse genetics system based on bacterial artificial chromosome and successfully generated a bat adenovirus-recombinant virus with E1A/B deletion to assess its anti-tumor effect as an oncolytic adenovirus, which targeted dog tumors.
|
